ROIV Has Its First Approval. Now Comes the Harder Part.
Lisraya wins dermatomyositis, but a boxed warning, a larger patient pool than advertised, and Phase 3 readouts define what the…
Warren Buffett Preparing for Imminent AI Meltdown?
August 29, 2026 Legendary Investors Dumping Nvidia. AI Meltdown Next? Bonus Content: ETF Inflows Don’t...
Branded Checkout, Braintree, Venmo: Lores Owns the Math
The $60.50-per-share floor is gone. PayPal’s three businesses must prove their worth on their own.
North America’s Trade Fork
August 28, 2026 Mexico negotiates while Canada retaliates, and the split is showing up in...
The greatest wealth transfer in American History
August 27, 2026 Shocking forecast for America Bonus Content: RUM’s $13.7B Contract Has a Catch...
WDAY Beat on Everything. The Guide Is the Problem.
Workday’s Q2 was nearly clean. A light subscription outlook pushed shares down after hours. That dislocation is worth examining carefully.
MRNA Went from $63 to $174 in a Day. Now Comes the Real Trade.
The Phase 3 melanoma win validated the mRNA oncology platform. The FDA submission and a pipeline of other cancer trials…
$56B Week Shows Where the Marginal Dollar Went
August 27, 2026 ETF flow data just flashed a leadership signal: hard assets are pulling...
Your Book Is Inside
August 26, 2026 Bonus Content: Crude Down 9%, Airlines Up: Reading the Reversal Sponsored In...
Component Monopolists vs. Boom Renters: Who Keeps the Money
Nvidia’s $108B guide is a cost signal as much as a revenue one. The question is which suppliers can actually…